Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients

Transplant Infectious Disease

Volumn 17, Issue 1, 2015, Pages 66-72

  Tohme, F A ^a   Kalil, R S ^a,b   Thomas, C P ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

BK virus; Calcineurin inhibitor sparing; Kidney transplantation; Sirolimus; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BK VIRUS INFECTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MOUTH ULCER; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; VIRUS LOAD; ADVERSE EFFECTS; BK VIRUS; DRUG EFFECTS; INCIDENCE; KIDNEY TRANSPLANTATION; POLYOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; VIREMIA;

ADULT; AGED; BK VIRUS; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TRANSPLANT RECIPIENTS; TUMOR VIRUS INFECTIONS; VIREMIA;

EID: 84923264624     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12347     Document Type: Article

References (17)

1. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5 (3): e1000363.
2. Wiseman AC. Polyomavirus nephropathy: a current perspective and clinical considerations. Am J Kidney Dis 2009; 54 (1): 131-142.
3. Kuppachi S, Thomas B, Kokko KE. BK virus in the kidney transplant patient. Am J Med Sci 2013; 345 (6): 482-488.
4. ™) results in the first year post-transplant and relationship to BK virus infection. Nephrol Dial Transplant 2012; 27 (6): 2565-2570.
5. Kuypers DR. Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol 2012; 8 (7): 390-402.
6. Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008; 85 (6): 850-854.
7. Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis 2006; 8 (2): 95-101.
8. Schold JD, Rehman S, Kayle LK, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22 (6): 626-634.
9. Beimler J, Sommerer C, Zeier M. The influence of immunosuppression on the development of BK virus nephropathy-does it matter? Nephrol Dial Transplant 2007; 22: 66-71.
10. Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68: 1834-1839.
11. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993; 696: 9-19.
12. Kelly PA, Gruber SA, Behbod F, et al. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997; 17: 1148-1156.
13. Liacini A, Seamone ME, Muruve DA, Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 2010; 90 (12): 1450-1457.
14. Demopoulos L, Polinsky M, Steele G, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008; 40 (5): 1407-1410.
15. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011; 11 (11): 2453-2462.
16. Peddi VR, Wiseman A, Chavin K, Slakey D. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev 2013; 27 (4): 97-107.
17. Cibrik D, Silva HT Jr, Vathsala A, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013; 95 (7): 933-942.